Pfizer agrees to update Chantix warnings

Share this content:

Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.

Share this content:
Scroll down to see the next article